Plain-English translation of NCT06527495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a medication that targets cancer cells, in patients with hepatocellular carcinoma (liver cancer). The researchers want to understand how your individual genes affect how well the medication works for you and what side effects you might experience. By studying your genetic makeup alongside your treatment response, they hope to personalize cancer care so each patient gets the best possible outcome with fewer unwanted effects.
works differently in different people, and some patients experience more side effects than others. This study exists to figure out which genetic markers can predict who will respond best to this medication, so doctors can eventually tailor treatment plans to each patient's unique biology.
You would take the medication by mouth twice daily at doses between 200–400 mg. Throughout the study, researchers will monitor how well the treatment is working, check for side effects, and collect blood or tissue samples to analyze your genes and how they relate to your response. The study will help doctors understand whether genetic testing could improve how this medication is prescribed in the future.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Egypt
Phase
Safety & dosing / Early efficacy
Sponsor
Assiut University
Enrollment target
~150 participants
Started
January 2023
Primary completion
December 2024
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mahmoud Nazih
Assiut University